Floatz logo

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER

Glioma, Malignant

Mustafa Khasraw, MBChB, MD, FRCP, FRACPmonoclonal_antibodyPhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Glioma, Malignant cohort.

Asset / SponsorPhaseRating
gsk1120212
St. Jude Children's Research Hospital
Phase 4B
Durvalumab
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phase 2B
Pembrolizumab
Essen Biotech
Phase 1/2CCC
Niraparib
Armando Santoro, MD
Phase 1/2CCC
TESTOSTERONE UNDECYLATE
Aminex Therapeutics, Inc.
Phase 1/2CC

View all 34 →

Same molecule, other indications

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
skin squamous cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
lung cancerDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →